Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
Hill R, Madureira PA, Ferreira B, Baptista I, Machado S, Colaҫo L, Dos Santos M, Liu N, Dopazo A, Ugurel S, Adrienn A, Kiss-Toth E, Isbilen M, Gure AO, Link W.
Hill R, et al. Among authors: baptista i.
Nat Commun. 2023 Jul 19;14(1):4341. doi: 10.1038/s41467-023-40050-1.
Nat Commun. 2023.
PMID: 37468494
Free PMC article.
No abstract available.